Clinical use of an orally acting converting enzyme inhibitor: captopril

H. R. Brunner, H. Gavras, B. Waeber, Stephen C Textor, G. A. Turini, J. P. Wauters

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

An orally active inhibitor of the angiotensin converting enzyme, SQ 14,225 or captopril, was administered to 14 normal volunteers to evaluate its efficacy in inhibiting the pressor response to exogenous angiotensin I. The degree of blockade was dose-related up to 10 mg of captopril. Increasing the dose further merely prolonged the duration of the blockade. Subsequently, 39 patients with various types of hypertension including some on maintenance hemodialysis were treated chronically with captopril, i.e., 50 to 200 mg twice daily. The blood pressure (BP) reduction observed 1 hour following administration of the inhibitor was directly related to the baseline plasma renin activity (PRA)(r = 0.67, p<0.001). Whenever blockade of the renin system alone did not lower BP to normal levels, additional sodium removal, e.g., by diuretics or ultrafiltration brought it under control. In eight additional untreated patients with essential hypertension, captopril induced an increase in renal plasma flow, which correlated significantly with PRA. Six normotensive patients with refractory congestive heart failure, were also studied hemodynamically following an acute dose of captopril. Cardiac function improved while peripheral resistance decreased. These data suggest that the renin angiotensin system participates actively in maintaining the BP of patients with hypertension and the afterload in patients with congestive heart failure, and that blockade of this sytem represents an effective advance in therapeutics.

Original languageEnglish (US)
Pages (from-to)558-566
Number of pages9
JournalHypertension
Volume2
Issue number4
StatePublished - 1980
Externally publishedYes

Fingerprint

Captopril
Enzyme Inhibitors
Renin
Blood Pressure
Heart Failure
Hypertension
Renal Plasma Flow
Angiotensin I
Ultrafiltration
Renin-Angiotensin System
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Vascular Resistance
Renal Dialysis
Healthy Volunteers
Sodium
Maintenance

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Brunner, H. R., Gavras, H., Waeber, B., Textor, S. C., Turini, G. A., & Wauters, J. P. (1980). Clinical use of an orally acting converting enzyme inhibitor: captopril. Hypertension, 2(4), 558-566.

Clinical use of an orally acting converting enzyme inhibitor : captopril. / Brunner, H. R.; Gavras, H.; Waeber, B.; Textor, Stephen C; Turini, G. A.; Wauters, J. P.

In: Hypertension, Vol. 2, No. 4, 1980, p. 558-566.

Research output: Contribution to journalArticle

Brunner, HR, Gavras, H, Waeber, B, Textor, SC, Turini, GA & Wauters, JP 1980, 'Clinical use of an orally acting converting enzyme inhibitor: captopril', Hypertension, vol. 2, no. 4, pp. 558-566.
Brunner HR, Gavras H, Waeber B, Textor SC, Turini GA, Wauters JP. Clinical use of an orally acting converting enzyme inhibitor: captopril. Hypertension. 1980;2(4):558-566.
Brunner, H. R. ; Gavras, H. ; Waeber, B. ; Textor, Stephen C ; Turini, G. A. ; Wauters, J. P. / Clinical use of an orally acting converting enzyme inhibitor : captopril. In: Hypertension. 1980 ; Vol. 2, No. 4. pp. 558-566.
@article{c43d938fe2a74cf5a34a1f0f43193112,
title = "Clinical use of an orally acting converting enzyme inhibitor: captopril",
abstract = "An orally active inhibitor of the angiotensin converting enzyme, SQ 14,225 or captopril, was administered to 14 normal volunteers to evaluate its efficacy in inhibiting the pressor response to exogenous angiotensin I. The degree of blockade was dose-related up to 10 mg of captopril. Increasing the dose further merely prolonged the duration of the blockade. Subsequently, 39 patients with various types of hypertension including some on maintenance hemodialysis were treated chronically with captopril, i.e., 50 to 200 mg twice daily. The blood pressure (BP) reduction observed 1 hour following administration of the inhibitor was directly related to the baseline plasma renin activity (PRA)(r = 0.67, p<0.001). Whenever blockade of the renin system alone did not lower BP to normal levels, additional sodium removal, e.g., by diuretics or ultrafiltration brought it under control. In eight additional untreated patients with essential hypertension, captopril induced an increase in renal plasma flow, which correlated significantly with PRA. Six normotensive patients with refractory congestive heart failure, were also studied hemodynamically following an acute dose of captopril. Cardiac function improved while peripheral resistance decreased. These data suggest that the renin angiotensin system participates actively in maintaining the BP of patients with hypertension and the afterload in patients with congestive heart failure, and that blockade of this sytem represents an effective advance in therapeutics.",
author = "Brunner, {H. R.} and H. Gavras and B. Waeber and Textor, {Stephen C} and Turini, {G. A.} and Wauters, {J. P.}",
year = "1980",
language = "English (US)",
volume = "2",
pages = "558--566",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Clinical use of an orally acting converting enzyme inhibitor

T2 - captopril

AU - Brunner, H. R.

AU - Gavras, H.

AU - Waeber, B.

AU - Textor, Stephen C

AU - Turini, G. A.

AU - Wauters, J. P.

PY - 1980

Y1 - 1980

N2 - An orally active inhibitor of the angiotensin converting enzyme, SQ 14,225 or captopril, was administered to 14 normal volunteers to evaluate its efficacy in inhibiting the pressor response to exogenous angiotensin I. The degree of blockade was dose-related up to 10 mg of captopril. Increasing the dose further merely prolonged the duration of the blockade. Subsequently, 39 patients with various types of hypertension including some on maintenance hemodialysis were treated chronically with captopril, i.e., 50 to 200 mg twice daily. The blood pressure (BP) reduction observed 1 hour following administration of the inhibitor was directly related to the baseline plasma renin activity (PRA)(r = 0.67, p<0.001). Whenever blockade of the renin system alone did not lower BP to normal levels, additional sodium removal, e.g., by diuretics or ultrafiltration brought it under control. In eight additional untreated patients with essential hypertension, captopril induced an increase in renal plasma flow, which correlated significantly with PRA. Six normotensive patients with refractory congestive heart failure, were also studied hemodynamically following an acute dose of captopril. Cardiac function improved while peripheral resistance decreased. These data suggest that the renin angiotensin system participates actively in maintaining the BP of patients with hypertension and the afterload in patients with congestive heart failure, and that blockade of this sytem represents an effective advance in therapeutics.

AB - An orally active inhibitor of the angiotensin converting enzyme, SQ 14,225 or captopril, was administered to 14 normal volunteers to evaluate its efficacy in inhibiting the pressor response to exogenous angiotensin I. The degree of blockade was dose-related up to 10 mg of captopril. Increasing the dose further merely prolonged the duration of the blockade. Subsequently, 39 patients with various types of hypertension including some on maintenance hemodialysis were treated chronically with captopril, i.e., 50 to 200 mg twice daily. The blood pressure (BP) reduction observed 1 hour following administration of the inhibitor was directly related to the baseline plasma renin activity (PRA)(r = 0.67, p<0.001). Whenever blockade of the renin system alone did not lower BP to normal levels, additional sodium removal, e.g., by diuretics or ultrafiltration brought it under control. In eight additional untreated patients with essential hypertension, captopril induced an increase in renal plasma flow, which correlated significantly with PRA. Six normotensive patients with refractory congestive heart failure, were also studied hemodynamically following an acute dose of captopril. Cardiac function improved while peripheral resistance decreased. These data suggest that the renin angiotensin system participates actively in maintaining the BP of patients with hypertension and the afterload in patients with congestive heart failure, and that blockade of this sytem represents an effective advance in therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=0019166965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019166965&partnerID=8YFLogxK

M3 - Article

C2 - 6995296

AN - SCOPUS:0019166965

VL - 2

SP - 558

EP - 566

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -